Breaking Finance News

A statement released earlier today by H.C. Wainwright about Cytokinetics Inc (NDAQ:CYTK) lowers the target price to $17.00

Only yesterday Cytokinetics Inc (NDAQ:CYTK) traded -1.01% lower at $8.02. CYTK’s 50-day average is $14.77 and its two hundred day average is $13.95. With the last close down 4.99% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.01% over the same period. Trading volume was down over the average, with 402,408 shares of CYTK changing hands under the typical 450,903

H.C. Wainwright lowered the target price of Cytokinetics Inc (NDAQ:CYTK) to $17.00 stating a potential upside of 1.12%.

On Monday July 31, 2017, Morgan Stanley released a statement about Cytokinetics Inc (NDAQ:CYTK) upped the target price from $0.00 to $24.00. At the time, this indicated a possible upside of 0.70%.

See Chart Below

Cytokinetics Inc (NDAQ:CYTK)

Cytokinetics Inc has a 52 week low of $8.77 and a 52 week high of $17.20 The company’s market cap is currently $0.

Also covering Cytokinetics Inc's target, a total of 6 brokerages have issued a ratings update on Cytokinetics Inc. The 12-month price target is $19.17 with one analyst rating the company a strong buy, five brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Cytokinetics Inc (NDAQ:CYTK)

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.